Veristat Launches InStat AI Platform for Clinical Trial Biostatistics

Veristat has announced the launch of InStat, a zero-code biostatistics platform designed to accelerate clinical trial data analysis. The company claims the system can deliver submission-ready tables, listings, and figures (TLF) in five days or less, compared to the four to six weeks sponsors typically wait after database lock.

The announcement came via Business Wire on May 13, 2026. Veristat will begin using InStat to deliver biostatistics services in June, with Clene Nanomedicine as the first clinical trial sponsor whose work was delivered using the platform.

Here's the technical architecture: AI agents translate biostatisticians' descriptions into precise specifications. Those specifications then drive a library of validated statistical engines that perform every analytical step. The key distinction—Veristat emphasizes this repeatedly—is that the system avoids LLM-generated analysis code, which carries regulatory exposure. Every output is backed by validated statistical engines and expert biostatistician review.

Michael Hotchkin, Chief Development Officer at Clene Nanomedicine, confirmed the platform's deployment in a real-world scenario. His company is advancing an NDA submission for CNM-Au8 with NfL biomarker concordance evidence as a core component of the accelerated approval pathway argument under Subpart H. Veristat produced the supporting NfL biomarker analyses with InStat, delivering tables in days rather than the weeks that similar analyses typically demand.

The financial stakes are concrete. At trial end, sponsors traditionally wait weeks for biostatisticians to manually analyze volumes of study data. Such delays to approval can cost sponsors $500,000 or more a day in potential, unrealized sales while patients remain burdened by their disease. (That's a lot of coffee spent waiting for spreadsheets to render.)

InStat also changes the collaboration workflow. Rather than sponsor and CRO commenting back and forth on drafts over weeks, sponsors can log into a secure online portal where they work directly with Veristat in real time to finalize biostatistical readouts. The platform is system-agnostic, meaning sponsors can use their preferred electronic data capture system and maintain their unique formatting.

Kyle McBride, Veristat Vice President, AI & Innovation, framed the approach as intentional risk management. "We intentionally put AI where it adds speed, not where it adds risk: assisting biostatisticians in translating analytical intent into precise specifications. Once that's right, everything downstream is trustworthy."

The platform builds on Veristat's foundation of two decades of proven biostatistical analysis. The company has supported more than 100 regulatory approvals with expertise in rare disease, neurological disease, oncology, and advanced therapies. This isn't a greenfield AI experiment—it's an automation layer on established methodology.

Veristat is hosting a limited-invite event featuring Ken Getz, Executive Director and Research Professor at the Tufts Center for the Study of Drug Development, on May 18, 2026 in Boston. The company is also offering demos on completed studies for potential customers.

There are caveats. The five-day timeline varies depending on type of trial, number of sites, and number of participants. The asterisk matters here—this isn't a universal guarantee. Complex studies with hundreds of sites and thousands of participants will face different constraints than smaller, focused trials.

The regulatory angle is worth examining closely. By avoiding LLM-generated analysis code and relying on validated statistical engines with human review, Veristat is positioning InStat as compliant-ready. But the FDA hasn't issued specific guidance on AI-assisted biostatistics workflows yet. The company's approach—human oversight on AI specifications—aligns with current regulatory expectations, but that could shift.

Whether this actually moves the needle on drug approval timelines depends on adoption. CROs and sponsors have entrenched workflows, and replacing manual biostatistical processes requires trust in the outputs. The Clene Nanomedicine case study provides proof of concept, but broader industry validation will take time.

Patients waiting for treatments won't feel the five-day difference directly. They'll only notice if drugs reach market faster. That's the real metric here—whether InStat translates into accelerated approvals, not just faster tables.

Whether sponsors actually pay for the speed premium remains the real question. The technology works on paper. The market will decide if it works in practice.

Artūras Malašauskas is an AI Systems Integrator with 20+ years of production-grade web engineering experience. He has designed, shipped, and scaled enterprise Python/PHP systems for logistics, SaaS, and public-sector clients. For the past year, he has focused exclusively on AI integrations: deploying open-source LLMs, building generative media pipelines (image, audio, video), and engineering multi-agent workflows for real production environments. His standard: reproducibility, security, cost-efficient inference—no vaporware. He documents and evaluates emerging AI tooling, separating verified capabilities from marketing noise. Technical editor at: muza-ai.eu, ai-verslas.lt, ai-naujinos.lt Connect on LinkedIn